Contrast-enhanced Ultrasonography Combined With Blue Dye as Dual-tracer for Sentinel Lymph Node Biopsy (Asclepius)
A Prospective Multi-center Study: Contrast-enhanced Ultrasonography Combined With Blue Dye as Dual-tracer for Sentinel Lymph Node Biopsy After Neoadjuvant Therapy in Breast Cancer
Sponsor: Affiliated Hospital of Guangdong Medical University
A NA clinical study on Breast Neoplasms and Neoadjuvant Therapy, this trial is ongoing. The trial is conducted by Affiliated Hospital of Guangdong Medical University and has accumulated 6 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status NA
Status: Not Yet Recruiting → Unknown Status
-
Apr 2023 — Sep 2023 [monthly]
Not Yet Recruiting NA
-
Oct 2021 — Apr 2023 [monthly]
Not Yet Recruiting NA
▶ Show 1 earlier version
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting NA
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affiliated Hospital of Guangdong Medical University
- First Affiliated Hospital of Shantou University Medical College
- First Affiliated Hospital, Sun Yat-Sen University
- The Seventh Affiliated Hospital of Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .